Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026

Cullinan Therapeutics, Inc.

Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.
Timelines for all other pipeline programs remain unchanged.
Updated corporate presentation posted to company website; no other changes disclosed in filing.

item 7.01 item 8.01 item 9.01

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-112949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.